Mid-Year Updates in AML Research with Uma Borate, MD and Naval Daver, MD image

Mid-Year Updates in AML Research with Uma Borate, MD and Naval Daver, MD

Jul 19, 2022
02:00PM - 03:30PM EDT
Online Event
Overview

Join us for a virtual HealthTree Round Table for AML on July 19th, 2022 at 2 pm EST. We will be joined by two AML experts to share mid-year updates about the latest research, emerging novel treatments and clinical trials from the recent ASCO and EHA conferences.

  • Uma Borate, MD from The James Comprehensive Cancer Center at Ohio State University
  • Naval Daver, MD from MD Anderson Cancer Center at The University of Texas

The annual American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA) meetings can be considered the “midterms” on the latest studies and findings in hematological malignancies—the American Society of Hematology (ASH) meeting is the annual final.  ASCO is held every year in late May/early June in Chicago, IL.  EHA rotates annually between major European cities.  This year EHA was held June 9-12th in Vienna, Austria.

User uploaded media

What are HealthTree Round Tables for AML?

These events are education programs for AML patients and caregivers on a variety of treatment and research issues. Each Round Table features presentations from internationally-recognized AML experts who will also participate in extensive Q&A time with audience members. In 2022, these events will take place either in person at a variety of US-based locations or virtually.

Agenda
02:05 PM
Key AML Research and Clinical Trials from ASCO
Dr. Borate will discuss the key highlights in AML research and clinical trials covered at the ASCO 2022 conference.
02:00 PM
Introduction and Announcements
Kerith introduces the agenda for the event and featured speakers, Dr. Uma Borate and Dr. Naval Daver
02:35 PM
Key AML Research and Clinical Trials from EHA
Dr. Daver will discuss the key highlights in AML research and clinical trials covered at the EHA 2022 conference.
03:05 PM
Question & Answer Session
Type your questions in the chat and the expert panel will answer them!
Speakers & Moderators
Healthtree contact Kerith Amen

Kerith Amen

Kerith joined HealthTree Foundation as a Community Co-Director for AML in 2022. She is a mother to a spirited eight-year-old daughter, Adair, and their beloved rescue, Violet. She lost her best friend and husband, Rob, to AML in March 2018. Kerith wishes she had a resource such as HealthTree for AML during Rob’s illness. She is a strong supporter of HealthTree's mission. She hopes that by sharing her experience, she may help other patients and caregivers navigate an AML diagnosis.
Healthtree contact Uma Borate, MBBS

Uma Borate, MBBS

Dr. Uma Borate is a hematologist specializing in the treatment of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN) and clonal cytopenias of unknown significance. She received her Master of Science in pathobiology and molecular medicine from the University of Cincinnati, and completed a fellowship in hematology/oncology at the University of Alabama. As a member of the Leukemia Research Program at the OSUCCC – James, her clinical and translational research focus is on novel therapeutics in myeloid diseases, with a special focus in disease progression from cytopenia and early-stage MDS to AML.
Healthtree contact Naval Daver, MD

Naval Daver, MD

Dr. Naval Daver is an Associate Professor in the Department of Leukemia at MD Anderson Cancer Center at the University of Texas. He completed his medical school from Grant Medical College and Sir J group of Hospitals Mumbai, followed by a residency and fellowship in hematology-oncology from Baylor College of Medicine. He is a clinical investigator with a focus on molecular and immune therapies in AML and Myelofibrosis and is principal investigator on over 25 ongoing institutional, national and international clinical trials in these diseases. He is especially interested in developing monoclonal and bispecific antibodies, immune checkpoint and vaccine based approaches in AML, MDS, and myelofibrosis and is leading a number of these trials at MD Anderson Cancer Center.